Geneseeq will share three mini-oral presentations and five poster studies at the World Conference on Lung Cancer (WCLC) 2023, which will be held on September 9-12th, 2023 in Singapore. These Geneseeq-collaborated studies cover novel prognostic and predictive biomarkers in lung cancer, molecular characterization of prognosis-related lung cancer subtypes, and multi-omics analysis of lung cancer genomic and transcriptomic features.

ID Title
MA12.05 The Patterns & Prognostic Value of Clonal Seeding in Lung Cancer Metastasis
MA14.10 Spatiotemporal Heterogeneity of Genomic and Transcriptomic Landscape of Multiple Lung Cancer by a Novel Multi-omics Algorithm
MA18.05 Biomarkers for Brain Metastases Risk and Survival Benefit of Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer
P1.10-01 Enrichment of FA/HR aberrations in ATM/ATR-mutated NSCLC was accompanied by distinct molecular features and poor prognosis
P1.21-17 DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer
P1.22-09 Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma
P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
EP12.01-49 Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions
Biomarker Cancer Research LUNGCANCER NSCLC Precision Oncology WCLC2023